2004 Cannabinoids Clinical Trials Data 
The Cannigma
JANUARY 13, 2023
A review of existing endocannabinoid system and migraine research from March 2022 identified many surveys, but fewer clinical research trials, and even fewer double-blind placebo studies. Chemovars classify cannabis based on the dominant cannabinoid, and there are three main types on the market right now. headaches per month.
Greencamp
AUGUST 16, 2018
Exploring the available research on ALS and cannabinoids. The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. The first study I will reference is from 2006, conducted on mice.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
OCTOBER 29, 2019
The PK data on cats shows there are differences in absorption between cats and dogs and that dosing may be different between these two species and that our chew form is likely to be more absorbable than oils in general. This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.
Greencamp
FEBRUARY 2, 2019
Even though cannabis and cannabinoid-derived pharmaceuticals are both frequently used by HIV/AIDS patients, several studies show that something interesting happens when cannabis is consumed. What is HIV and how is it manifested? Human immunodeficiency virus (HIV), as the name implies, harms the immune system. Cannabis as medicine against HIV.
Cannabis Law Report
JANUARY 18, 2019
Several of these products have already completed or been approved for clinical trials in Israel. public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. CNBX) is a U.S
Cannabis Law Report
JULY 12, 2019
International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.
Cannabis Law Report
NOVEMBER 24, 2021
At the same time, the outlook on cannabis research data is largely positive. The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). Data collection. This offers a more denotative approach to complement the data.
Expert insights. Personalized for you.
132 
Let's personalize your content